Clinical Trial Update: Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity [Phase 4]

View source ↗

Summary

This Phase 4 trial of extended-release oxybutynin for neurogenic detrusor overactivity was terminated. Results were posted in July 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Detrusor Overactivity
• Neurogenic Detrusor Overactivity
• Overactive Bladder

Drugs mentioned

• Ditropan XL (oxybutynin chloride)

Snippet

Sponsor: Janssen-Cilag Ltd.,Thailand | Conditions: Detrusor Function, Overactive | Phase 4 | Status: TERMINATED | Results posted: 2013-07-31